Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.64 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15821706 | 0.83 | FFAR1 (0.64) | FFAR1FFAR4P4HTMKEAP1SLC22A12 | |
| SCHEMBL23021014 | 0.83 | GABRP (0.56) | FFAR1FFAR4P4HTMAKR1B1LMNA | |
| SCHEMBL26968221 | 0.80 | CHEK1 (0.46) | FFAR1FFAR4 | |
| SCHEMBL14109903 | 0.79 | CYP4F2 (0.54) | FFAR1FFAR4 | |
| SCHEMBL5871891 | 0.79 | GRM2 (0.42) | FFAR1FFAR4 | |
| SCHEMBL10390335 | 0.77 | FFAR1 (0.45) | FFAR1FFAR4 | |
| SCHEMBL7962602 | 0.77 | P4HTM (0.68) | FFAR1FFAR4P4HTMKEAP1LMNA | |
| SCHEMBL2960380 | 0.75 | FFAR1 (0.47) | FFAR1FFAR4P4HTMKEAP1SLC22A12 | |
| SCHEMBL2323227 | 0.75 | GRM2 (0.41) | FFAR1FFAR4 | |
| SCHEMBL5028148 | 0.75 | NAMPT (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110475785-B | Peptide compound, method for producing same, composition for screening, and method for selecting peptide compound | 富士胶片株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | FFAR1 2851/4885FFAR4 3518/4885P4HTM 243/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | FFAR1 2851/4885FFAR4 3518/4885P4HTM 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.